Itoh et al. «Inhibition
of Urokinase Receptor (uPAR) Expression by RNA - Cleaving Catalytic DNA (DNAzyme) Containing Antisense uPAR», Molecular Therapy, 5 (5): S134, 2002.
Figure 8 (C) shows that kahweol - treatment induces a dose - dependent decrease in the levels
of urokinase in HUVEC conditioned media, with an almost complete inhibition at 50 µM kahweol.
Urokinase (uPA): The αMUPA mouse lineage has the addition
of a urokinase gene and has a longer life span as a result.
Thrombosis recanalization by paeoniflorin through the upregulation
of urokinase - type plasminogen activator via the MAPK signaling pathway.
Not exact matches
Everyone has
urokinase plasminogen activator receptor (uPAR), a healthy molecule «tethered» in place to various types
of cells.
This protease activates hepatocyte growth factor (HGF) and
urokinase plasminogen activator (uPA), two proteins thought to be involved in the growth and motility
of cancer cells, particularly carcinomas, and in the vascularization
of tumors.
Urokinase - type plasminogen activator receptor regulates a novel pathway
of fibronectin matrix assembly requiring Src - dependent transactivation
of epidermal growth factor receptor.
They include its effects on endothelial cell «differentiation» to yield tubular - like structures, endothelial and tumor cell proliferation, apoptosis, and migration, as well as its effects on extracellular matrix remodelling enzyme activities
of matrix metalloproteinase - 2 (MMP - 2) and
urokinase - type plasminogen activator (uPA).
Our results in the zymographic assays for gelatinase and
urokinase activities clearly showed that, in fact, kahweol was able to inhibit the expression
of both MMP - 2 and uPA, identifying them as two relevant molecular targets for kahweol.
In addition, it also enhances the body's production
of both plasmin and other clot - dissolving agents, including
urokinase (endogenous).
Urokinase comes along, carried on the surface
of platelets and certain white blood cells, to finish the job.